COVID-19 vaccines and multiple sclerosis disease-modifying therapies

被引：11

作者：

Giovannoni, Gavin ^{[1
]}

Hawkes, Christopher H. ^{[1
]}

Lechner-Scott, Jeannette ^{[1
]}

Levy, Michael ^{[1
]}

Yeh, E. Ann ^{[1
]}

Baker, David ^{[1
]}

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2021年 / 53卷

关键词：

IMMUNITY;

D O I：

10.1016/j.msard.2021.103155

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页数：3

共 27 条

[1] Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies [J].

Achiron, Anat ;

Mandel, Mathilda ;

Dreyer-Alster, Sapir ;

Harari, Gil ;

Magalashvili, David ;

Sonis, Polina ;

Dolev, Mark ;

Menascu, Shay ;

Flechter, Shlomo ;

Falb, Rina ;

Gurevich, Michael .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14

[2]

Apostolidis S.A., ALTERED CELLULAR HUM

[3] COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases [J].

Baker, D. ;

Roberts, C. A. K. ;

Pryce, G. ;

Kang, A. S. ;

Marta, M. ;

Reyes, S. ;

Schmierer, K. ;

Giovannoni, G. ;

Amor, S. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2020, 202 (02) :149-161

[4] The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis [J].

Baker, David ;

Pryce, Gareth ;

James, Louisa K. ;

Marta, Monica ;

Schmierer, Klaus .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 44

[5] The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic [J].

Baker, David ;

Amor, Sandra ;

Kang, Angray S. ;

Schmierer, Klaus ;

Giovannoni, Gavin .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 43

[6] Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations [J].

Barry, Brian ;

Erwin, April A. ;

Stevens, Jessica ;

Tornatore, Carlo .

NEUROLOGY AND THERAPY, 2019, 8 (02) :241-250

[7] Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform [J].

Bhaskaran, Krishnan ;

Bacon, Sebastian ;

Evans, Stephen J. W. ;

Bates, Chris J. ;

Rentsch, Christopher T. ;

MacKenna, Brian ;

Tomlinson, Laurie ;

Walker, Alex J. ;

Schultze, Anna ;

Morton, Caroline E. ;

Grint, Daniel ;

Mehrkar, Amir ;

Eggo, Rosalind M. ;

Inglesby, Peter ;

Douglas, Ian J. ;

McDonald, Helen, I ;

Cockburn, Jonathan ;

Williamson, Elizabeth J. ;

Evans, David ;

Curtis, Helen J. ;

Hulme, William J. ;

Parry, John ;

Hester, Frank ;

Harper, Sam ;

Spiegelhalter, David ;

Smeeth, Liam ;

Goldacre, Ben .

LANCET REGIONAL HEALTH-EUROPE, 2021, 6

[8] Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection [J].

Bigaut, K. ;

Kremer, L. ;

Fleury, M. ;

Lanotte, L. ;

Collongues, N. ;

de Seze, J. .

REVUE NEUROLOGIQUE, 2021, 177 (10) :1237-1240

[9] Rituximab-induced changes in hematolymphoid tissues found at autopsy [J].

Cioc, Adina M. ;

Vanderwerf, Steven M. ;

Peterson, Bruce A. ;

Robu, Valentin G. ;

Forster, Colleen L. ;

Pambuccian, Stefan E. .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (04) :604-612

[10] The COVID-19 pandemic and the use of MS disease-modifying therapies [J].

Giovannoni, Gavin ;

Hawkes, Chris ;

Lechner-Scott, Jeannette ;

Levy, Michael ;

Waubant, Emmanuelle ;

Gold, Julian .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39

← 1 2 3 →